Cao YX, et al. - A number of pooled analyses with small sample sizes have suggested that proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9-mAbs) might be effective at reducing circulating lipoprotein (a) (Lp[a]) levels, so researchers conducted this meta-analysis of 27 randomized clinical trials with a total of 11,864 participants to better assess if PCSK9-mAbs are efficacious at lowering serum Lp(a) concentrations. They found that a significant reduction of circulating Lp(a) levels with PCSK9-mAbs was reported in the studies. Data showed that 150 mg alirocumab biweekly and 140 mg evolocumab monthly offered the greatest reduction. Safety was in accordance with previous reports. In meta-regression analyses, the reduction in Lp(a) levels grew greater as the intensity of low-density lipoprotein cholesterol levels reduction increased, during PCSK9-mAb treatment.